The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
Gottfried E. Konecny
Research Funding - Amgen
Paul Haluska
No relevant relationships to disclose
Fritz Janicke
No relevant relationships to disclose
Jalid Sehouli
No relevant relationships to disclose
Matthias W. Beckmann
No relevant relationships to disclose
Gabriele Feisel
No relevant relationships to disclose
Martin Pölcher
No relevant relationships to disclose
Lynda Roman
No relevant relationships to disclose
Achim Rody
No relevant relationships to disclose
Beth Karlan
No relevant relationships to disclose
Isabelle Laure Ray-Coquard
No relevant relationships to disclose
Diane M. Provencher
No relevant relationships to disclose
Noa Ben-Baruch
No relevant relationships to disclose
Paul H. Cottu
No relevant relationships to disclose
Hsiao-Wang Chen
No relevant relationships to disclose
Chen Wang
No relevant relationships to disclose
Judy Dering
No relevant relationships to disclose
Sylvie Jacod
Employment or Leadership Position - Translational Research In Oncology
Vincent Houe
Employment or Leadership Position - Translational Research In Oncology
Dennis J. Slamon
Employment or Leadership Position - Translational Research In Oncology
Stock Ownership - Amgen